Hapten Sciences is a privately held biopharmaceutical company based in Memphis, Tennessee. The company’s mission is to identify and efficiently develop novel early-stage products that will significantly contribute to the health and well being of people around the world.  The company’s initial product candidate (HPT-721) is a novel, small molecule that acts like a vaccine to prevent the extremely painful itching and rash (contact dermatitis) caused by exposure to urushiol (yoo-ROO-she-ol) oil in poison ivy, poison oak and poison sumac plants. Next steps in development include final formulation analysis, pivotal toxicology studies, cGMP manufacturing and filing the Investigational New Drug (IND) Application.  The company plans to begin clinical trials in the coming months.

www.haptensciences.com